- Home
- CHRS vs OXSQ Comparison
CHRS vs OXSQ Comparison
Compare CHRS & OXSQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHRS | OXSQ |
|---|---|---|
| Founded | 2010 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.0M | 151.1M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | CHRS | OXSQ |
|---|---|---|
| Price | $1.32 | $1.74 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.02 | N/A |
| AVG Volume (30 Days) | ★ 943.2K | 829.9K |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | ★ 24.28% |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.34 | N/A |
| Revenue | ★ $277,728,000.00 | $40,142,565.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $67.29 | $2.27 |
| P/E Ratio | $1.05 | ★ N/A |
| Revenue Growth | ★ 152.07 | N/A |
| 52 Week Low | $0.71 | $1.56 |
| 52 Week High | $1.89 | $2.87 |
Technical Indicators
Market Signals| Indicator | CHRS | OXSQ |
|---|---|---|
| Relative Strength Index (RSI) | 48.00 | 34.46 |
| Support Level | $1.34 | $1.72 |
| Resistance Level | $1.43 | $1.87 |
| Average True Range (ATR) | 0.08 | 0.04 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 52.36 | 12.12 |
Price Performance
Historical ComparisonAbout CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About OXSQ Oxford Square Capital Corp.
Oxford Square Capital Corp is a closed-end, non-diversified management investment company with a focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. its capital is generally used by its corporate borrowers to finance organic growth, acquisitions, recapitalizations, and working capital. The group invests in various industries such as Structured Finance, IT Consulting, Business Services, Utilities, Software, Healthcare, Telecommunication Services, Plastics Manufacturing and Diversified Insurance.